3 ASX 200 healthcare stocks with 'strong return potential' in 2025

MotleyFool10:28

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502009217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502009217","market":"hk","top_or_hot":-1,"title":"3 ASX 200 healthcare stocks with 'strong return potential' in 2025","media":"MotleyFool","content":"<div>\n<p>Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity ...</p>\n\n<a href=\"https://www.fool.com.au/2025/01/10/3-asx-200-healthcare-stocks-with-strong-return-potential-in-2025/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 ASX 200 healthcare stocks with 'strong return potential' in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 ASX 200 healthcare stocks with 'strong return potential' in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-10 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2025/01/10/3-asx-200-healthcare-stocks-with-strong-return-potential-in-2025/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity ...</p>\n\n<a href=\"https://www.fool.com.au/2025/01/10/3-asx-200-healthcare-stocks-with-strong-return-potential-in-2025/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-200-healthcare-stocks-with-strong-return-potential-in-2025/","article_id":"2502009217","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502009217","pubTimestamp":1736476121,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Three S&P/ASX 200 Index healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity Asset Management. Commenting on the investment outlook for 2025, Bolger said, \"Overall, the investment outlook for 2025 is positive but cautious.\" He added:  Lower interest rates and strong equity dynamics present opportunities but risks like geopolitical tensions and uneven global growth require careful navigation. A flexible, growth-focused approach will be essential to manage challenges and seize opportunities.  Citing high valuations and declining earnings, Bolger said he's cautious on ASX 200 bank stocks. But he has a positive outlook for the healthcare sector. ASX 200 healthcare stocks facing demand growth in 2025 Drilling into three specific ASX 200 healthcare stocks he's bullish on, Bolger named global pathology provider Sonic Healthcare Ltd , biotech giant CSL Ltd , and sleep disorder treatme","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","SHL.AU":"SONIC HEALTHCARE LTD","RMD.AU":"Resmed DRC","BK7501":"新冠治疗股","CSL.AU":"CSL LIMITED","BK7511":"ESG概念","BK7007":"医疗保健设备","BK7508":"医药生物股","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技"},"translate_title":"2025年3只具有“强劲回报潜力”的ASX 200医疗保健股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1,"RMD.AU":1,"SHL.AU":1,"XJO.AU":1},"content_text":"Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity Asset Management. Commenting on the investment outlook for 2025, Bolger said, \"Overall, the investment outlook for 2025 is positive but cautious.\" He added:  Lower interest rates and strong equity dynamics present opportunities but risks like geopolitical tensions and uneven global growth require careful navigation. A flexible, growth-focused approach will be essential to manage challenges and seize opportunities.  Citing high valuations and declining earnings, Bolger said he's cautious on ASX 200 bank stocks. But he has a positive outlook for the healthcare sector. ASX 200 healthcare stocks facing demand growth in 2025 Drilling into three specific ASX 200 healthcare stocks he's bullish on, Bolger named global pathology provider Sonic Healthcare Ltd (ASX: SHL), biotech giant CSL Ltd (ASX: CSL), and sleep disorder treatment company ResMed Inc (ASX: RMD). \"Companies like CSL, ResMed, and Sonic Healthcare are set to benefit from growing demand for pathology, blood plasma, and medical devices,\" he said. \"These companies are trading at attractive prices and have strong return potential.\" What's been happening with the Aussie healthcare companies? ResMed reported its first quarter FY 2025 results on 25 October. The ASX 200 healthcare stock gained 5.9% on the day after reporting an 11% year on year lift in revenue for the three months to 30 September of US$1.22 billion. 34% Operating profit was up 34% from the prior corresponding quarter. Increased demand for the company's sleep devices and masks drove revenue growth. ResMed also reported growth across its Residential Care Software segment. \"Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business,\" ResMed CEO Mick Farrell said at the time. ASX 200 healthcare stock Sonic reported its full FY 2024 results on 22 August. Core financial metrics included a 9.8% year-on-year increase in revenue to $8.97 billion. Net profit after tax (NPAT) was down 25% from FY 2023 to $511 million. \"The 2024 financial year can be summarised as a transition period for Sonic Healthcare, as we moved away from the impacts of the pandemic towards business as usual,\" Sonic CEO Colin Goldschmidt said at the time. As for CSL, the biotech company reported its FY 2024 results on 13 August. The ASX 200 healthcare stock achieved an 11% year-on-year increase in revenue (in constant currency) to US$14.8 billion. And net profit after tax before amortisation was up 11% to US$2.91 billion. \"Our largest franchise, the immunoglobulins portfolio, delivered exceptional growth driven by significant patient demand, and the recovery in CSL Behring's gross margin is progressing to plan,\" CSL CEO Paul McKenzie said following the results.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502009217"}